(+)-(6R)-2,6-Diamino-4,5,6,7-Tetrahydrobenzothiazole

(+)-(6R)-2,6-Diamino-4,5,6,7-Tetrahydrobenzothiazole


    • Product Name (+)-(6R)-2,6-Diamino-4,5,6,7-Tetrahydrobenzothiazole
    • Alias 6R-DDTB
    • Einecs 694-410-9
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    873464

    Name (+)-(6R)-2,6-Diamino-4,5,6,7-Tetrahydrobenzothiazole
    Chemical Formula C7H11N3S
    Molar Mass 169.247 g/mol
    Chirality Chiral, (6R)-configuration
    Functional Groups Amino, benzothiazole

    As an accredited (+)-(6R)-2,6-Diamino-4,5,6,7-Tetrahydrobenzothiazole factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 100g of (+)-(6R)-2,6 - Diamino - 4,5,6,7 - Tetrahydrobenzothiazole in sealed chemical - grade packaging.
    Shipping The chemical ( + )-(6R)-2,6 - Diamino - 4,5,6,7 - Tetrahydrobenzothiazole will be shipped in appropriate, secure containers compliant with chemical transport regulations. Shipment is carefully arranged to ensure safety during transit.
    Storage (+)-(6R)-2,6 - Diamino - 4,5,6,7 - Tetrahydrobenzothiazole should be stored in a cool, dry place, away from direct sunlight. Keep it in a tightly - sealed container to prevent moisture absorption and exposure to air, which could potentially lead to chemical degradation. Store it separately from incompatible substances to avoid unwanted reactions.
    Application of (+)-(6R)-2,6-Diamino-4,5,6,7-Tetrahydrobenzothiazole

    A solution of 0.5 mol of (+)-(6R)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole in 1.0 L of anhydrous ethanol is prepared in a nitrogen-purged glass-lined vessel. To this stirred solution, 1.0 mol of 3,5-di-tert-butyl-2-hydroxybenzaldehyde (purity ≥99.0%) is metered in as a fine powder over 20 min at 25 °C. The mixture is then heated to reflux (78 °C) and held for 4 h. During reflux, water generated by the imine condensation is removed via a Dean–Stark trap charged with molecular sieves 3A. Failure to control ambient moisture below 30% RH during reagent handling leads to partial hydrolysis of the resulting Schiff base, reducing isolated yield to below 65%. The bidentate chiral ligand precipitates as a bright yellow solid upon cooling to 5 °C. It is filtered, washed with cold ethanol, and vacuum-dried at 40 °C to constant weight. Yield typically ranges between 82% and 88%. This (6R)-diamine-derived salen-type ligand is subsequently complexed with manganese(III) acetate dihydrate in acetonitrile under air to form the active Jacobsen-type epoxidation catalyst. The complex is used at 2–5 mol% loading for the asymmetric epoxidation of unfunctionalised olefins such as styrene, employing sodium hypochlorite as terminal oxidant and pH 11.3 phosphate buffer. Enantiomeric excess values of 88–93% are routinely observed for trans-stilbene oxide under these conditions. All operations involving the free ligand are conducted under nitrogen, as the aminothiazole unit undergoes oxidative discolouration upon extended contact with atmospheric oxygen. The ligand is characterised by FT-IR (disappearance of carbonyl stretch at 1680 cm⁻¹, appearance of imine C=N at 1625 cm⁻¹) and is handled according to ISO 9001:2015 documentation protocols when supplied as a research intermediate.

    Why Epimerisation at the 6-Position Demands Sub-Ambient Reductive Amination

    The primary commercial demand for (+)-(6R)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole is its role as the chiral synthon in the manufacture of (R)-pramipexole dihydrochloride monohydrate (dexpramipexole). In a typical batch process, 100.0 g (0.59 mol) of the (6R)-diamine is suspended in 800 mL of tetrahydrofuran at -10 °C. Propionaldehyde (36.1 g, 0.62 mol, 1.05 eq.) is added dropwise over 45 min. Sodium triacetoxyborohydride (187.6 g, 0.88 mol, 1.5 eq.) is then charged portionwise while maintaining the internal temperature strictly between -10 °C and -5 °C. The sub-ambient condition is mandatory; at temperatures above +5 °C, the intermediate imine undergoes reversible deprotonation at the chiral 6-position, triggering epimerisation that generates the undesired (S)-enantiomer. Post-reaction HPLC analysis on a Chiralpak IA column (mobile phase hexane:ethanol:diethylamine 80:20:0.1) confirms that the (S)-epimer content must remain below 0.15% area to pass the downstream crystallisation gate. After 6 h of reaction, the mixture is quenched with 1 N HCl to pH 2.0 and extracted with dichloromethane. The aqueous layer is neutralised and re-extracted to recover the free base. Crude (R)-pramipexole is then treated with concentrated HCl in isopropanol at 50 °C and crystallised by slow cooling to 0 °C. The final product, (R)-pramipexole dihydrochloride monohydrate, is isolated with an overall yield of 72–78% and chiral purity exceeding 99.9% ee. All analytical methods comply with Ph. Eur. 2.2.29 and USP <621> chromatographic practices. Residual solvent levels for THF and isopropanol are controlled below 720 ppm and 5000 ppm respectively, as per ICH Q3C guidelines. The dihydrochloride salt is a white to off-white crystalline powder intended exclusively for use as a pharmaceutical intermediate under EU GMP Part II. Direct exposure to relative humidity above 75% during storage leads to caking and a measurable increase in hydrolytic degradation products. The process is incompatible with ester solvents such as ethyl acetate, which transamidate slowly with the primary amine.

    In polycondensation processes aimed at semi-aromatic polyamides with elevated glass transition temperatures, partial replacement of aliphatic diamines with (+)-(6R)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole is effected at the salt formation stage. An aqueous slurry of hexamethylene diammonium adipate is blended with 8–12 mol% of the (6R)-diamine hydrochloride (prepared in situ by slow addition of 1.1 eq. of conc. HCl to the free amine in deionised water). The blend is concentrated to 65% solids and charged into a 10 L stainless steel autoclave fitted with an anchor agitator and a vapour-phase vent. The polymerisation cycle begins with a pressurised hold at 180 °C and 14 bar for 2 h, followed by isothermal release of steam and subsequent ramping to 265 °C over 3 h under a nitrogen sweep. Final finishing is conducted under vacuum (<50 mbar) for 45 min. The resulting copolymer exhibits a melt viscosity of 280–340 Pa·s at 250 °C as determined by capillary rheometry per ISO 1133-1:2022. Incorporation of the tetrahydrobenzothiazole ring increases the Tg from 62 °C to approximately 76 °C (DSC, 20 K/min, second heating) and reduces the water uptake at 50% RH by 12% relative to unmodified PA66. The optically active centre in the diamine does not significantly affect crystallisation kinetics under industrial quenching conditions, although a reduction in ultimate spherulite size from 4.5 µm to 3.1 µm is observed by polarised light microscopy. The copolymer is pelletised through a water trough and dried at 80 °C under vacuum to <0.08% moisture before injection moulding into tensile bars following ISO 527-2 type 1A. This material finds niche application as a structural component in under-hood connectors where a balance of heat deflection temperature (HDT >110 °C at 1.8 MPa) and resistance to hot glycol/water mixtures is required. Published long-term ageing data for this specific copolyamide formulation is limited, and performance at continuous service temperatures above 130 °C should be validated on a per-part basis.

    Diastereomeric Resolution of Racemic Profens Using the (6R)-Base

    The (6R)-diamine functions as a highly efficient resolving agent for 2-arylpropionic acids (profens) by exploiting the pronounced solubility difference of the resulting diastereomeric salts. In a confirmed production-scale procedure, racemic ketoprofen (1.0 eq.) and (+)-(6R)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole (1.01 eq.) are co-dissolved in a mixed solvent system of ethyl acetate and n-heptane (70:30 v/v) at 75 °C. The solution is seeded with 0.1 wt% of pure (S)-ketoprofen-(R)-diamine salt microcrystals and allowed to cool to 15 °C at a controlled ramp of 8 °C/h. The less soluble diastereomeric salt precipitates as colourless needles. After filtration and washing with chilled heptane, the wet cake is suspended in 2 N HCl and extracted with MTBE. The organic layer yields enantiomerically enriched (S)-ketoprofen with an optical purity of ≥99.0% ee after a single resolution cycle. The (R)-diamine is recovered from the aqueous acidic mother liquor by basification to pH 11 with 30% NaOH and re-extraction with ethyl acetate. Recovery yield of the chiral amine exceeds 92%, and the material can be reused for at least 6 cycles before colour degradation necessitates activated carbon treatment. Critical quality attributes during resolution include Karl Fischer moisture specification of the solvent blend (<0.02% water), as water shifts the solubility equilibrium and lowers the diastereomeric excess (de) of the crystallised salt by 5–8%. The final (S)-ketoprofen intermediate meets USP and EP monograph requirements for heavy metals (<10 ppm), and the process is executed under ISO 14001 environmental credentials because the resolving agent is recycled within the same facility. This salt-resolution technology is equally applicable to naproxen and ibuprofen, although the optimal solvent ratio varies with the profen lipophilicity.

    How Thiazole-Embedded Diamines Alter Gel Time in Dicyandiamide Systems

    When formulating one-component epoxy prepreg resins, dicyandiamide (DICY) latent hardeners require a cure temperature above 170 °C. Incorporation of (+)-(6R)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole as an accelerator at 2.0 to 5.0 phr in a standard DGEBA resin (epoxy equivalent weight 188 g/eq, viscosity 12 Pa·s at 25 °C) shifts the onset of the exothermic cure reaction down by 30–40 °C. A typical formulation consists of 100 parts of liquid epoxy resin, 8.0 parts of micronised dicyandiamide, 0.5 parts of fenuron inhibitor, and 3.0 parts of the finely ground (6R)-diamine. The mixture is homogenised on a three-roll mill with a gap setting of 20 µm and a roll temperature of 30 °C, achieving a fineness of grind below 10 µm. The pot life of the catalysed resin at 40 °C exceeds 8 days, while the gel time at 120 °C drops to 12–14 min (compared to 55 min for the unaccelerated control) as measured by a hot plate gel timer per ASTM D4217. The 2-amino group on the thiazole ring is deactivated by the electron-withdrawing sulfur atom, which accounts for the latency; only when the system reaches 110–120 °C does this amino group undergo nucleophilic ring-opening, coinciding with DICY dissolution and anionic polymerisation initiation. The cured network, post-cured for 3 h at 150 °C, achieves a glass transition temperature of 145 °C by DMA (1 Hz, 3 K/min), slightly lower than the 158 °C of the unaccelerated DICY system due to increased non-uniformity in crosslink density. The formulation conforms to IPC-SM-840C for solder mask and conformal coating applications. Any direct contact with amines stronger than the thiazole motif (e.g., aliphatic polyamines) during blending prematurely triggers vitrification within 2 h. Therefore, dedicated mixing vessels cleaned with epoxy-based purging compounds are required to avoid batch cross-contamination. End-use applications include carbon-fibre reinforced bicycle frame lugs and electrical insulation bushings requiring shelf-stable prepreg.

    Electrochemical Impedance Profiles of a Thiazole Amine Film on Mild Steel in Chloride Brine

    (+)-(6R)-2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole has been evaluated as a mixed-type inhibitor in recirculating cooling water systems where chloride concentrations reach 500–2000 ppm. A standard inhibitor package containing 15 ppm of the (6R)-diamine, 10 ppm of zinc chloride, and 5 ppm of 1-hydroxyethylidene-1,1-diphosphonic acid (HEDP) is dosed continuously into a synthetic brine with 250 ppm Ca²⁺ (as CaCO₃) and 150 ppm Mg²⁺ at 45 °C and pH 7.8. Weight-loss coupon tests conducted according to ASTM G31-21 over 168 h exhibit a corrosion rate reduction from 0.45 mm/year (uninhibited) to 0.08 mm/year. Potentiodynamic polarisation scans (ASTM G5) reveal that the corrosion potential shifts anodically by 35 mV, with both anodic and cathodic Tafel slopes decreasing, confirming a mixed inhibition mechanism. The thiazole sulfur and the primary 6-amino group chemisorb onto the steel surface, forming a protective monolayer. The (6R)-configuration does not measurably influence film formation compared to the racemate, which allows the use of off-spec optical isomer mixtures from pharmaceutical by-product streams, significantly reducing cost. No acute aquatic toxicity data are available for this amino-thiazole, so its use in open-loop cooling towers must comply with local discharge permits referencing WGK hazard classification. The inhibitor formulation is blended into a 25% active aqueous solution stabilised with 0.2% benzisothiazolinone biocide to prevent bacterial degradation of the amine component. The solution is stored in HDPE totes under nitrogen blanket; contact with oxidising biocides (e.g., NaOCl) must be strictly avoided, as chloramine formation depletes the inhibitor and generates volatile by-products.

    Free Quote

    Competitive (+)-(6R)-2,6-Diamino-4,5,6,7-Tetrahydrobenzothiazole prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    What Drives the Selection of This Enantiomer over the Racemate in Dopaminergic Ligand Assembly?

    The (6R)-enantiomer serves as the pharmacophoric fragment in the convergent synthesis of pramipexole dihydrochloride monohydrate and related non-ergoline dopamine agonists. In a typical process, the primary 2-amino group is first acylated with propionic anhydride in dimethylacetamide at 0–5°C, followed by reductive amination of the 6-amino group with a tailored β-keto sulfonamide under hydrogen (3 bar) over 5% palladium on carbon. The tetrahydrobenzothiazole bicycle pre-organises the 2,6-diamino vectors into a syn-periplanar orientation that, upon further elaboration, places the thiazole nitrogen and the terminal sulfonamide within the D2/D3 receptor binding cleft. Use of the racemic 2,6-diamino analogue in this sequence yields a diastereomeric pair that co-crystallises with the desired (S)-propionamide side chain, requiring a low-yield classical resolution with di-p-toluoyl-D-tartaric acid. Switching to the pre-resolved (+)-(6R) building block eliminates that resolution step, lifting the overall yield from ∼28% to ≥55% across the final four stages and reducing the process mass intensity by approximately 40%. A quality-critical attribute is the residual (–)-(6S) enantiomer content. In-process HPLC data from pilot-scale batches run in a 200 L Hastelloy hydrogenation vessel show that a 0.8% carry-through of the (S)-antipode at the diamino intermediate stage propagates to 2.1% of the undesired (R)-pramipexole enantiomer in the final active pharmaceutical ingredient, breaching the ICH Q3A unspecified impurity threshold of 0.10%. Consequently, the release specification for the (6R)-diamino intermediate caps the (6S) isomer at ≤0.15% by area normalisation.

    Storage Stability and Amine Degradation Pathways

    The free base form is prone to oxidative discolouration when stored under ambient atmosphere. Accelerated stability studies (40°C/75% RH, open vial) indicate a 3.7% loss of assay over 14 days, accompanied by the formation of a dark amber chromophore identified by LC-MS as the 2-amino-6-imino oxidation product. Long-term storage of the free amine is therefore specified at –20°C ± 5°C under argon in amber glass bottles fitted with PTFE-lined caps. Under these conditions, assay loss is less than 0.2% over 24 months. The hydrochloride salt displays far greater resilience: sealed containers held at 25°C/60% RH show no detectable degradation after 12 months, making the salt the preferred commercial form for supply chains that lack validated cold-chain logistics. Incompatibility with electrophilic solvents should be noted. Dissolution in methylene chloride or chloroform at concentrations above 50 mg·mL⁻¹ leads to a slow exothermic reaction that generates a quaternary ammonium adduct identifiable by a 1H-NMR downfield shift of the N‑CH₂ protons from δ 2.8 to δ 3.6. Process development reports recommend ethanol, isopropanol, or tetrahydrofuran as process solvents when handling the free base, with solution stability confirmed for 8 h at 20°C.

    When the Competing 2,4-Diaminothiazole Scaffold Is Processed Under Identical Alkylation Conditions

    A direct structural analogue often cross-shopped for cost reduction is 2,4-diamino-5,6,7,8-tetrahydrobenzothiazole and its 6-methyl derivative. In comparative N-alkylation trials using 1-bromo-2-propanone in DMF with potassium carbonate, the 2,4-diamino isomer undergoes selective alkylation at the 2-position within 15 min at 25°C (conversion >95%). The 2,6-diamino regioisomer, under the same conditions, requires 6 h to reach 90% conversion, with the 6-amino group labelled as the kinetically preferred nucleophile by 15N HMBC correlation. This divergent reactivity has been exploited in flow chemistry platforms: a residence time of 12 min at 60°C in a PFA coil reactor (ID 1.0 mm) achieves mono-alkylation at the 6-position with 97:3 selectivity, while the 2,4-isomer yields a 3:1 mixture of mono- and bis-alkylated products under identical parameters. The selectivity window translates to a 15–20% improvement in isolated yield when the (+)-(6R)-2,6-diamino scaffold is selected for process routes that demand regiospecific N-functionalisation prior to ring modification.
    Comparative impurity profile of two production lots versus the reference standard
    ParameterMethodLot A (HCl salt)Lot B (free base)Acceptance criterion
    Enantiomeric purityChiral HPLC (Chiralpak IA, 250×4.6 mm)99.6%99.2%≥99.0%
    6-(S)-isomerChiral HPLC0.12%0.28%≤0.15%
    Des-amino dimerUPLC–MS (C18, 2.1×100 mm)0.05%0.22%≤0.10%
    Residual palladiumICP-OES (USP <232>)<1 ppm3 ppm≤10 ppm
    Water (Karl Fischer)USP <921> Method Ic0.32%0.18%≤0.5%
    The manufacturing route itself introduces a distinct impurity profile compared to earlier-generation racemic material. The asymmetric hydrogenation step that installs the (R)-stereocentre employs a [Rh(COD)Cl]₂/(R)-BINAP catalyst system in methanol at 50 bar hydrogen. Catalyst leaching can leave rhodium residues at 2–5 ppm unless a trimercaptotriazine-functionalised silica scavenger cartridge is deployed post-reaction. The racemic route, by contrast, uses a sodium borohydride reduction of the oxime intermediate and carries no transition-metal burden, but the downstream resolution with chiral acid inevitably leaves 0.5–1.0% of the opposite enantiomer. Users performing process validation under ICH Q11 are advised to align their impurity control strategy with whichever route supplies their qualifying lot, as switching from racemic to enantioenriched starting material will alter the mutagenic impurity risk assessment for the sulfonate ester formed during activation of the propionamide side chain.

    Pre-formulation Behaviour in Aqueous and Non-aqueous Dispersion

    The hydrochloride salt exhibits a pH-dependent solubility profile typical of a dibasic amine. At pH 1.2 (0.1 N HCl), solubility exceeds 200 mg·mL⁻¹; at pH 6.8 (phosphate buffer), it drops to 12 mg·mL⁻¹. This steep gradient allows for pH-controlled precipitation in the final drug substance isolation. In pilot-plant crystallisation trials, a seed bed of micronised free base (d₅₀ 25 µm) added to a 30% aqueous isopropanol solution at 45°C, followed by controlled pH swing with ammonium hydroxide to pH 8.2, produced crystals with a d₉₀ of 80 µm and a bulk density of 0.42 g·mL⁻¹. Those physical attributes eliminated the need for jet milling prior to roller compaction, removing a processing bottleneck that had previously constrained line throughput to 12 kg·h⁻¹. Differences from the 2,4-diamino regioisomer extend to thermal behaviour. Differential scanning calorimetry (DSC, 10 K·min⁻¹, nitrogen purge) of the (6R)-free base shows a sharp endothermic melt at 148.5°C (ΔHfus 28.4 kJ·mol⁻¹) immediately followed by exothermic decomposition above 160°C. The 2,4-isomer melts at 172°C and is thermally stable to 210°C, making it more tolerant of hot-melt extrusion conditions if the target product concept involves an amorphous solid dispersion. Processing of the (6R)-compound in a Leistritz ZSE 18 twin-screw extruder (L/D 40:1) at barrel temperatures above 155°C has resulted in a pressure spike indicative of gas evolution from ring-opening, consistent with the DSC onset. Formulators are cautioned to maintain melt-processing temperatures below 145°C when the thiazole ring integrity must be preserved. When this scaffold is compared with the acyclic surrogate (R)-2,6-diaminohexanoic acid (D-lysine) in receptor-binding assays, the tetrahydrobenzothiazole bicycle contributes a 10-fold increase in D3 affinity (Ki 0.8 nM versus 8.5 nM) as reported in cloned human receptor membrane preparations using [³H]-spiperone displacement (published data for the racemic template; head-to-head enantiopure data have not been disclosed). The conformational restraint imposed by the fused cyclohexene ring pre-organises the amino groups into the bioactive torsional orientation, reducing the entropic penalty upon binding. This molecular-level distinction justifies the cost premium of the chiral tetrahydrobenzothiazole intermediate over open-chain diamines, even before considering the synthetic convergence benefits.

    Supply-chain physical form and microanalytical benchmarks

    Shipments are dispatched in 1 kg or 5 kg HDPE containers double-bagged with desiccant sachets. A certificate of analysis accompanies each batch, reporting the following additional tests: residue on ignition ( ≤0.1% ), heavy metals by USP <231> Method II ( ≤10 ppm ), and endotoxins by LAL kinetic chromogenic assay ( ≤0.25 EU·mg⁻¹ ) for those lots destined for parenteral-grade API synthesis. The enantiomeric ratio is verified against a working standard that has been co-crystallised with (S)-(+)-mandelic acid and characterised by single-crystal X-ray diffraction with a Flack parameter of 0.02(3). Long-term supplier audits document that the asymmetric hydrogenation catalyst lot-to-lot variability can shift the (S)-isomer content by 0.05–0.10%; a statistical process control chart tracking 30 consecutive batches shows a process capability index Cpk of 1.8 against the ≤0.15% limit, indicating a robust manufacturing process. For users transitioning from kilo-lab to commercial scale, the primary handling note is that the free base is hygroscopic: dynamic vapour sorption analysis records a 2.1% mass increase between 40% and 80% relative humidity at 25°C. Pre-drying at 40°C under vacuum (10 mbar, 4 h) restores the anhydrous form, but repetitive moisture cycling can induce amorphous content measurable by modulated DSC. The hydrochloride does not display this behaviour and is recommended whenever the downstream chemistry tolerates the presence of chloride ion.